CHARLOTTESVILLE, VA / ACCESSWIRE / February 15, 2024 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Winter Wrap-Up MicroCap Rodeo Conference, which will be held virtually Tuesday, February 20 through Friday, February 23, 2024.

Cary Claiborne, Chief Executive Officer of Adial, is scheduled to present on Tuesday, February 20 at 11:30 a.m. Eastern Time. To register and access the presentation please visit Adial Pharmaceuticals (webcaster4.com). Mr. Claiborne will also be available to host one-on-one meetings with approved investors on Thursday, February 22, and Friday, February 23.

To register for a one-on-one meeting, please visit registration at MicroCap Rodeo.

About the Winter Wrap-Up MicroCap Rodeo Conference

The Winter Wrap Up MicroCap Rodeo Conference is unique, as it is run by money managers and investors for money managers and investors. Throughout a 4-day period, investors can harness top stock ideas for their portfolios. The investors will meet with executive management teams from approximately 20 MicroCap companies across a wide swath of industries and garner an understanding into the key value drivers and potential trends for 2024. The first two days of the conference are solely presentations, so investors are not conflicted with 1x1 schedules and can focus on the presentations, as well as learn more about the companies before meeting them. The following two days are for quality 1x1 meetings. For more information please contact info@microcaprodeo.com.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of AUD in heavy drinking patients and was recently investigated in the Company's ONWARD pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company's proprietary companion diagnostic genetic test. ONWARD showed promising results in reducing heavy drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at .

Forward Looking Statements

This communication contains certain"forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the combination of the Company's genetic diagnostic and AD04 providing a tailored treatment solution for those who suffer from AUD and OUD, transforming the lives of millions affected by AUD and other dependencies by the Company combining a tool to predict which patients are most likely to benefit from AD04 treatment with AD04's clinical track record of reducing heavy drinking days among patients with specific genotypes, the addressable market for AD04 being approximately $40 billion among patients with the target genotypes in the U.S. alone, bringing a personalized approach to addiction with AD04 and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views,and they involve certain risks and uncertainties, including, among others, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2022, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required bylaw.

Contact:

Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: ADIL@crescendo-ir.com

SOURCE: Adial Pharmaceuticals, Inc.